TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04782687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral drug that comes in 20 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
Study: NCT05456113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
Study: NCT06627881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Endurance Circuit Program
Description: Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval program with rope
Description: Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
Study: NCT06627413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration
Study: NCT05456113

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
Study: NCT04804072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)
Description: MOUD for OUD
Study: NCT06627413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration
Study: NCT06077708

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3K2
Description: Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
Study: NCT04804072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV testing
Description: HIV testing
Study: NCT06077708

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
Study: NCT06498063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
Study: NCT06627413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-E2 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-E3 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-X2 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-X5 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Study: NCT05730816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous infusion of normal saline.
Study: NCT05302661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: re-education
Description: Contact patients by phone or wechat and guide them
Study: NCT05246904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitting algorithm
Description: The best fitting algorithm will be selected by the audiologist (arm 1) or software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitting algorithm
Description: The best fitting algorithm will be selected by the audiologist (arm 1) or software.
Study: NCT04891731

Intervention type: DRUG
Intervention: AI or TAM
Description: This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.

Intervention type: DRUG
Intervention: AI or TAM
Description: This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
Study: NCT06138288

Intervention type: BEHAVIORAL
Intervention: acupressure
Description: The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
Study: NCT05594043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6598
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6598
Description: Oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT06498063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% NaCl).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon and exendin 9-39
Description: Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon and exendin 9-39
Description: Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon and exendin 9-39
Description: Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
Study: NCT04804072

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: HIV testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV treatment for participants living with HIV not already in care
Description: HIV treatment for participants living with HIV not already in care
Study: NCT06670586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional in vitro fertilization
Description: Fertilization via conventional In Vitro Fertilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection (ICSI)
Description: Fertilization via intracytoplasmic sperm injection
Study: NCT06600802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
Study: NCT06407401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet for healthy behaviors
Description: All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet for healthy behaviors
Description: All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
Study: NCT04804072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP for participants without HIV
Description: PrEP for participants without HIV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
Description: Testing and referral for vaccination or treatment for HAV and HBV

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
Description: Testing and referral for vaccination or treatment for HAV and HBV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing and referral for treatment for hepatitis C virus (HCV)
Description: Testing and referral for treatment for HCV
Study: NCT06270797

Intervention type: PROCEDURE
Intervention: intubation for general anesthesia
Description: routine intubation for general anesthesia

Intervention type: PROCEDURE
Intervention: intubation for general anesthesia
Description: routine intubation for general anesthesia
Study: NCT06282172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL-785-7
Description: Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
Study: NCT04950985

Intervention type: OTHER
Intervention: Observational Study
Description: Observational study
Study: NCT04959019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised combined endurance and resistance training (CERT)
Description: Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed supervised combined endurance and resistance training (CERT)
Description: After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
Study: NCT04804072

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing and referral for treatment for hepatitis C virus (HCV)
Description: Testing and referral for treatment for HCV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) testing and treatment
Description: STI testing and treatment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sexually transmitted infection (STI) testing and treatment
Description: STI testing and treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care
Description: Primary care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm reduction services
Description: Harm reduction services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Harm reduction services
Description: Harm reduction services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation
Description: Peer navigation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer navigation
Description: Peer navigation
Study: NCT06407401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet for healthy behaviors
Description: All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
Study: NCT04804072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 testing and referral for further evaluation, care and/or treatment
Description: COVID-19 testing and referral for further evaluation, care and/or treatment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 testing and referral for further evaluation, care and/or treatment
Description: COVID-19 testing and referral for further evaluation, care and/or treatment
Study: NCT06780267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129; low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129; high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 placebo
Description: HRS-2129 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 placebo
Description: HRS-2129 placebo
Study: NCT04830397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution 1x daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution 1x daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution 1x daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate
Description: Ophthalmic solution 1x daily
Study: NCT05208281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 1.0-2.0-3.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 2.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 3.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 3.0 mg/kg
Study: NCT04731103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir (ABC)
Description: Tablets or oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Description: Tablet or oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
Description: Tablet or oral solution
Study: NCT06104124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT06144645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS, intermittent stimulation
Description: transcutaneous vagus nerve stimulation, intermittent stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS, continuous stimulation
Description: transcutaneous vagus nerve stimulation, continuous stimulation
Study: NCT06305598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given SC
Study: NCT06613984

Intervention type: BIOLOGICAL
Intervention: Bretovameran
Description: Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
Study: NCT06613139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2305
Description: Test drug: YHP2305 Comparator: YHR2404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2305
Description: Test drug: YHP2305 Comparator: YHR2404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2404
Description: Test drug: YHP2305 comparator: YHR2404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2404
Description: Test drug: YHP2305 comparator: YHR2404
Study: NCT06611813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy in Combination with Toripalimab
Description: Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
Study: NCT06627413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Study: NCT05854563

Intervention type: OTHER
Intervention: Observational only, all subjects; measure DNA mutation and proteomic survey.
Description: Observational only, all subjects; measure DNA mutation and proteomic survey.

Intervention type: OTHER
Intervention: Observational only, all subjects; measure DNA mutation and proteomic survey.
Description: Observational only, all subjects; measure DNA mutation and proteomic survey.
Study: NCT06611813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR+ HER2 breast cancer
Description: During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.